Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PHR

Phreesia Inc

Feb 12 • 04:00PM ET

11.86

-0.64 -5.12 %

Healthcare • Health Information Services • USA • NYSE

Peers: VEEV UNH TDOC EVH GEHC ADP MASI BLKB HIMS HSTM

| Held by: VTI IWM VB VXF VBK IWO VTWO FESM SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-0.10	Insider Own	7.94%	Shs Outstand	60.23M	Perf Week	-5.80%
Market Cap	715.01M	Forward P/E	22.50	EPS next Y	0.53	Insider Trans	-6.30%	Shs Float	55.50M	Perf Month	-28.47%
Enterprise Value	619.07M	PEG	-	EPS next Q	0.07	Inst Own	100.58%	Short Float	5.82%	Perf Quarter	-47.87%
Income	-5.38M	P/S	1.54	EPS this Y	108.07%	Inst Trans	-4.44%	Short Ratio	2.14	Perf Half Y	-58.60%
Sales	463.20M	P/B	2.23	EPS next Y	540.63%	ROA	-1.35%	Short Interest	3.23M	Perf YTD	-29.91%
Book/sh	5.32	P/C	6.72	EPS next 5Y	-	ROE	-1.87%	52W High	32.76 -63.80%	Perf Year	-58.28%
Cash/sh	1.76	P/FCF	14.29	EPS past 3/5Y	24.57% 16.05%	ROIC	-1.66%	52W Low	11.67 1.63%	Perf 3Y	-68.70%
Dividend Est.	-	EV/EBITDA	27.55	Sales past 3/5Y	25.33% 27.46%	Gross Margin	61.90%	Volatility	5.48% 4.57%	Perf 5Y	-85.03%
Dividend TTM	-	EV/Sales	1.34	EPS Y/Y TTM	93.62%	Oper. Margin	-1.45%	ATR (14)	0.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.43	Sales Y/Y TTM	14.33%	Profit Margin	-1.16%	RSI (14)	19.73	Recom	1.15
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	127.89%	SMA20	-15.70%	Beta	0.66	Target Price	28.32
Payout	-	Debt/Eq	0.03	Sales Q/Q	12.67%	SMA50	-25.77%	Rel Volume	2.38	Prev Close	12.50
Employees	2082	LT Debt/Eq	0.01	Earnings	Dec 08 AMC	SMA200	-48.50%	Avg Volume	1.51M	Price	11.86
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	17600.00% 0.27%	Trades		Volume	3,580,431	Change	-5.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-09-26	Resumed	RBC Capital Mkts	Outperform	$26
Jan-09-26	Initiated	Wells Fargo	Overweight	$30
Dec-09-25	Initiated	Barclays	Overweight	$26
Nov-13-25	Initiated	BMO Capital Markets	Outperform	$32
Sep-05-25	Resumed	DA Davidson	Buy	$33
Aug-27-25	Initiated	Mizuho	Outperform	$36
Jan-08-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$24 → $32
Feb-26-24	Initiated	Truist	Buy	$35
Jan-17-24	Upgrade	DA Davidson	Neutral → Buy	$30 → $32
Jan-03-24	Initiated	Barclays	Overweight	$29
Apr-12-23	Initiated	Stephens	Overweight	$37
Jan-04-23	Reiterated	Needham	Buy	$35 → $40
Dec-13-22	Upgrade	Citigroup	Neutral → Buy	$40
Dec-09-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$31 → $34
Oct-13-22	Initiated	DA Davidson	Neutral	$25
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$40
Apr-14-22	Initiated	Guggenheim	Buy	$45
Jan-06-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$57 → $41
Dec-02-21	Initiated	Jefferies	Buy	$70
Sep-02-21	Reiterated	Needham	Buy	$70 → $81

Show Previous Ratings

Feb-11-26 04:05PM	Phreesia CEO Chaim Indig Named to The Software Reports Top 50 CEOs of 2025 (Business Wire) -5.12%
Feb-04-26 06:32PM	Can Waystar Still Stand Up to Rising Competition? (MarketBeat)
Jan-24-26 08:55AM	Phreesia price target lowered to $30 from $35 at DA Davidson (TipRanks)
Jan-15-26 08:39AM	As AI use in healthcare rises, Waystar is riding the wave (Yahoo Finance)
Jan-03-26 07:20AM	Klaviyo, Wingstop among Stephens Best Ideas for 2026 (TipRanks)
03:40AM	Loading…
Dec-23-25 03:40AM	Phreesia Stock Has Been Crushed. We're Standing By Our Pick. (Barrons.com)
Dec-15-25 11:10PM	Phreesia (PHR) Analyst Model Updated to Reflect Company's Latest Financial Guidance for 2026-2027 (Insider Monkey)
Dec-10-25 09:35AM	Phreesia (PHR) Loses 32.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-09-25 06:17PM	Why Phreesia Stock Plummeted by 23% Today (Motley Fool) -23.31%
08:44AM	Phreesia Posts Solid Earnings But Shares Drop Anyway (24/7 Wall St.)
12:00AM	Phreesia Inc (PHR) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Dec-08-25 05:30PM	Phreesia (PHR) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
04:11PM	Phreesia: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	Phreesia Announces Third Quarter Fiscal 2026 Results and Introduces Fiscal 2027 Outlook (Business Wire)
Dec-04-25 04:05PM	Phreesias Megan Turco Named to MM+M 40 Under 40 (Business Wire)
09:15AM	Loading…
Dec-03-25 09:15AM	Stay Ahead of the Game With Phreesia (PHR) Q3 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Dec-01-25 10:00AM	Phreesia (PHR) Earnings Expected to Grow: Should You Buy? (Zacks)
Nov-20-25 05:20PM	Veeva Systems (VEEV) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +5.25%
09:35AM	After Plunging 18.2% in 4 Weeks, Here's Why the Trend Might Reverse for Phreesia (PHR) (Zacks)
Nov-19-25 04:05PM	Phreesia Named to the 2025 Deloitte Technology Fast 500 (Business Wire)
Nov-13-25 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-12-25 06:00PM	KORU Medical Systems, Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-25 04:04PM	Phreesia Sets Release Date for Fiscal Third Quarter 2026 Results (Business Wire)
Oct-20-25 10:49AM	Phreesia (PHR) Fell in Q3 Despite Reporting Better Results (Insider Monkey)
Sep-16-25 06:49AM	Beckers Names Phreesias Sara DiNardo as one of 2025s Rising Stars of Healthcare (Business Wire)
Sep-10-25 12:20AM	Truist Financial Raises PT on Pheresis From $35 to $36, Keeps Buy Rating (Insider Monkey)
Sep-05-25 03:05AM	Phreesia Inc (PHR) Q2 2026 Earnings Call Highlights: Record Revenue and First Positive Net Income (GuruFocus.com) -9.87%
Sep-04-25 06:00PM	Phreesia (PHR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:45PM	Phreesia (PHR) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:48PM	Phreesia: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Phreesia Announces Second Quarter Fiscal 2026 Results (Business Wire)
04:03PM	Phreesia to Acquire AccessOne, Expanding Its Suite of Payment Solutions (Business Wire)
Sep-02-25 04:04PM	Phreesia Launches VoiceAI, a Conversational AI Solution to Transform Call Management in Healthcare (Business Wire)
Aug-29-25 09:15AM	Exploring Analyst Estimates for Phreesia (PHR) Q2 Earnings, Beyond Revenue and EPS (Zacks)
Aug-27-25 05:15PM	Phreesia Gains A New Bull. Why the Stock Is a Buy. (Barrons.com)
Aug-14-25 05:15PM	P3 Health Partners Inc. (PIII) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-12-25 04:05PM	Phreesia Named to the 2025 Capterra Shortlist for Patient Engagement and Medical Scheduling (Business Wire)
Aug-08-25 07:10AM	Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-07-25 04:05PM	Phreesia Sets Release Date for Fiscal Second Quarter 2026 Results (Business Wire)
Aug-06-25 06:10PM	Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
01:00AM	Phreesia Is Turning Profitable. Buy This Small-Cap Healthcare Tech Leader. (Barrons.com)
Jul-30-25 04:05PM	New Research Illustrates Gaps in COPD Care and the Need for Better Patient-Provider Communication (Business Wire)
Jul-25-25 07:45AM	3 Red-Hot Growth Stocks to Buy in 2025 (Motley Fool)
Jul-15-25 12:00PM	All You Need to Know About Phreesia (PHR) Rating Upgrade to Buy (Zacks)
Jul-09-25 04:05PM	Phreesia Named in Black Book Researchs List of 2025s Top-Rated Vendors for Patient Access and Front-End Management Solutions in Revenue Cycle Management (Business Wire)
Jul-08-25 08:49AM	Indig: AI has been wildly effective for us, our providers, and patients (CNBC TV)
Jun-12-25 04:05PM	Beckers Names Phreesias Kristin Roberts as one of 2025s 100 Women in Health IT to Know (Business Wire) -5.57%
Jun-02-25 12:00PM	Phreesia (PHR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-29-25 11:33PM	Q1 Earnings Outperformers: Phreesia (NYSE:PHR) And The Rest Of The Healthcare Technology for Providers Stocks (StockStory)
08:55AM	Morning Movers: Abercrombie & Fitch skyrockets following first quarter results (TipRanks)
03:03AM	Phreesia Inc (PHR) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic AI ... (GuruFocus.com)
May-28-25 12:25PM	PHR Q1 Earnings Call: Revenue Misses, Profitability Surges Amid Product Expansion (StockStory) -6.61%
12:25PM	PHR Q1 Earnings Call: Profitability Surges Amid Product Expansion (StockStory)
09:30AM	Here's What Key Metrics Tell Us About Phreesia (PHR) Q1 Earnings (Zacks)
08:15AM	Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:17AM	Phreesia (NYSE:PHR) Surprises With Q1 Sales (StockStory)
07:09AM	Phreesia: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:03AM	Phreesia Announces First Quarter Fiscal 2026 Results (Business Wire)
May-27-25 03:03AM	Phreesia (PHR) Reports Q1: Everything You Need To Know Ahead Of Earnings (StockStory)
May-26-25 09:15AM	Gear Up for Phreesia (PHR) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
May-21-25 12:01AM	3 Reasons to Sell PHR and 1 Stock to Buy Instead (StockStory)
May-08-25 07:20AM	Privia Health (PRVA) Misses Q1 Earnings Estimates (Zacks)
May-07-25 07:05PM	TruBridge (TBRG) Lags Q1 Earnings Estimates (Zacks)
May-06-25 04:05PM	Phreesia Updates May 28, 2025, Earnings Release Information for Fiscal First Quarter 2026 Results (Business Wire)
Apr-29-25 09:01AM	1 Cash-Heavy Stock with Impressive Fundamentals and 2 to Ignore (StockStory)
06:40AM	Phreesia Sets Release Date for Fiscal First Quarter 2026 Results (Business Wire)
05:06AM	Winners And Losers Of Q4: Evolent Health (NYSE:EVH) Vs The Rest Of The Healthcare Technology for Providers Stocks (StockStory)
Apr-28-25 05:04AM	Unpacking Q4 Earnings: Omnicell (NASDAQ:OMCL) In The Context Of Other Healthcare Technology for Providers Stocks (StockStory)
Apr-11-25 01:15PM	Buy Certara After The FDA Announcement (Seeking Alpha)
Apr-04-25 09:55AM	Wall Street Analysts Think Phreesia (PHR) Could Surge 28.02%: Read This Before Placing a Bet (Zacks)
Mar-19-25 09:03AM	1 Small-Cap Stock with Solid Fundamentals and 2 to Ignore (StockStory) +6.34%
Mar-14-25 05:02AM	Q4 Earnings Review: Healthcare Technology for Providers Stocks Led by Phreesia (NYSE:PHR) (StockStory)
Mar-13-25 04:06PM	Phreesia Named to G2s List of 2025 Best Healthcare Software Products (Business Wire) +6.93%
07:30AM	Q4 2025 Phreesia Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Phreesia Inc (PHR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow (GuruFocus.com)
Mar-12-25 05:30PM	Phreesia (PHR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:40PM	Phreesia (NYSE:PHR) Posts Better-Than-Expected Sales In Q4 But Stock Drops (StockStory)
04:17PM	Phreesia: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	Phreesia Announces Fourth Quarter Fiscal 2025 Results (Business Wire)
Mar-11-25 08:02AM	Phreesia (PHR) To Report Earnings Tomorrow: Here Is What To Expect (StockStory) +5.74%
Feb-14-25 07:02AM	Phreesia (PHR) Moves 5.6% Higher: Will This Strength Last? (Zacks)
Feb-11-25 01:45PM	Why Insiders Are Selling Phreesia, Inc. (PHR) Recently (Insider Monkey)
06:48AM	Phreesias Sally Thayer Selected as a Top Woman Leader in Software (Business Wire)
Feb-07-25 04:15PM	Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2025 Results (Business Wire)
Jan-29-25 09:15AM	Phreesia, Inc. (PHR) Soars to 52-Week High, Time to Cash Out? (Zacks)
Jan-14-25 12:00PM	Phreesia (PHR) Upgraded to Buy: Here's Why (Zacks)
Jan-08-25 09:55AM	Should You Buy Phreesia (PHR) After Golden Cross? (Zacks) +5.37%
Dec-20-24 09:55AM	Wall Street Analysts See a 25% Upside in Phreesia (PHR): Can the Stock Really Move This High? (Zacks) +5.54%
Dec-12-24 07:17AM	Phreesia price target lowered to $30 from $34 at Baird (TipRanks)
Dec-10-24 08:13AM	Q3 2025 Phreesia Inc Earnings Call (Thomson Reuters StreetEvents) +11.60%
02:01AM	Phreesia Inc (PHR) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow (GuruFocus.com)
Dec-09-24 06:00PM	Phreesia (PHR) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Phreesia: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Phreesia Announces Third Quarter Fiscal 2025 Results (Business Wire)
Dec-06-24 09:15AM	Curious about Phreesia (PHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Nov-22-24 06:48AM	Phreesia Named to The Software Reports Top 100 Software Companies for the Third Consecutive Year (Business Wire)
Nov-07-24 04:26AM	Phreesia (PHR) Moves 13.9% Higher: Will This Strength Last? (Zacks)
Nov-01-24 06:48AM	Phreesia Sets Release Date for Fiscal Third Quarter 2025 Results (Business Wire)

Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VanDuyn Amy Beth	SVP, Human Resources	Jan 16 '26	Sale	16.36	2,202	36,018	157,349	Jan 20 05:11 PM
VanDuyn Amy Beth	SVP, Human Resources	Jan 15 '26	Sale	16.38	687	11,253	159,551	Jan 20 05:11 PM
Roberts Evan	President, Provider Solutions	Jan 16 '26	Sale	16.36	6,268	102,524	826,554	Jan 20 05:11 PM
Roberts Evan	President, Provider Solutions	Jan 15 '26	Sale	16.38	1,810	29,647	832,822	Jan 20 05:11 PM
Linetsky David	President, Network Solutions	Jan 16 '26	Sale	16.36	6,038	98,762	223,942	Jan 20 05:10 PM
Linetsky David	President, Network Solutions	Jan 15 '26	Sale	16.38	1,743	28,549	229,980	Jan 20 05:10 PM
Indig Chaim	Chief Executive Officer	Jan 16 '26	Sale	16.36	9,595	156,943	1,361,535	Jan 20 05:08 PM
Indig Chaim	Chief Executive Officer	Jan 15 '26	Sale	16.38	3,038	49,761	1,371,130	Jan 20 05:08 PM
Hoffman Allison C	General Counsel & Secretary	Jan 16 '26	Sale	16.36	3,995	65,345	169,661	Jan 20 05:08 PM
Hoffman Allison C	General Counsel & Secretary	Jan 15 '26	Sale	16.38	1,106	18,116	173,656	Jan 20 05:08 PM
Gandhi Balaji	Chief Financial Officer	Jan 16 '26	Sale	16.36	4,687	76,664	150,569	Jan 20 05:07 PM
Gandhi Balaji	Chief Financial Officer	Jan 15 '26	Sale	16.38	975	15,970	155,256	Jan 20 05:07 PM
Hui Yvonne	Principal Accounting Officer	Jan 15 '26	Sale	16.17	379	6,128	29,166	Jan 16 05:09 PM
Hui Yvonne	Principal Accounting Officer	Jan 14 '26	Sale	16.36	365	5,971	29,545	Jan 16 05:09 PM
Linetsky David	Officer	Jan 16 '26	Proposed Sale	16.36	6,038	98,762		Jan 16 04:27 PM
VanDuyn Amy Beth	Officer	Jan 16 '26	Proposed Sale	16.36	2,202	36,018		Jan 16 04:17 PM
Hoffman Allison C	Officer	Jan 16 '26	Proposed Sale	16.36	3,995	65,345		Jan 16 04:03 PM
Indig Chaim	Officer	Jan 16 '26	Proposed Sale	16.36	9,595	156,944		Jan 16 03:50 PM
Gandhi Balaji	Officer	Jan 16 '26	Proposed Sale	16.36	4,687	76,664		Jan 16 03:48 PM
Roberts Evan	Officer	Jan 16 '26	Proposed Sale	16.36	6,268	102,524		Jan 16 03:44 PM
VanDuyn Amy Beth	Officer	Jan 15 '26	Proposed Sale	16.38	687	11,253		Jan 15 03:34 PM
Hoffman Allison C	Officer	Jan 15 '26	Proposed Sale	16.38	1,106	18,116		Jan 15 03:27 PM
Linetsky David	Officer	Jan 15 '26	Proposed Sale	16.38	1,743	28,549		Jan 15 03:24 PM
Gandhi Balaji	Officer	Jan 15 '26	Proposed Sale	16.38	975	15,970		Jan 15 03:23 PM
Roberts Evan	Officer	Jan 15 '26	Proposed Sale	16.38	1,810	29,647		Jan 15 03:18 PM
Indig Chaim	Officer	Jan 15 '26	Proposed Sale	16.38	3,038	49,761		Jan 15 03:13 PM
Hui Yvonne	Officer	Jan 15 '26	Proposed Sale	16.17	379	6,128		Jan 15 10:31 AM
Hui Yvonne	Officer	Jan 14 '26	Proposed Sale	16.36	365	5,971		Jan 14 03:12 PM
VanDuyn Amy Beth	SVP, Human Resources	Jan 08 '26	Sale	17.01	2,602	44,252	160,238	Jan 12 05:06 PM
Roberts Evan	President, Provider Solutions	Jan 08 '26	Sale	17.01	6,317	107,434	834,632	Jan 12 05:05 PM
Linetsky David	President, Network Solutions	Jan 08 '26	Sale	17.01	6,106	103,845	231,723	Jan 12 05:01 PM
Indig Chaim	Chief Executive Officer	Jan 08 '26	Sale	17.01	8,440	143,540	1,374,168	Jan 12 05:00 PM
Hui Yvonne	Principal Accounting Officer	Jan 08 '26	Sale	17.47	372	6,499	29,910	Jan 12 04:58 PM
Hoffman Allison C	General Counsel & Secretary	Jan 08 '26	Sale	17.01	6,585	111,992	174,762	Jan 12 04:55 PM
Gandhi Balaji	Chief Financial Officer	Jan 08 '26	Sale	17.01	8,009	136,210	156,231	Jan 12 04:51 PM
Gandhi Balaji	Officer	Jan 08 '26	Proposed Sale	17.01	8,009	136,210		Jan 08 04:50 PM
Indig Chaim	Officer	Jan 08 '26	Proposed Sale	17.01	8,440	143,540		Jan 08 04:43 PM
Roberts Evan	Officer	Jan 08 '26	Proposed Sale	17.01	6,317	107,434		Jan 08 04:32 PM
VanDuyn Amy Beth	Officer	Jan 08 '26	Proposed Sale	17.01	2,602	44,252		Jan 08 04:28 PM
Hoffman Allison C	Officer	Jan 08 '26	Proposed Sale	17.01	6,585	111,992		Jan 08 04:27 PM
Linetsky David	Officer	Jan 08 '26	Proposed Sale	17.01	6,106	103,845		Jan 08 04:21 PM
Hui Yvonne	Officer	Jan 08 '26	Proposed Sale	17.47	372	6,499		Jan 08 09:43 AM
VanDuyn Amy Beth	SVP, Human Resources	Dec 19 '25	Option Exercise	4.71	18,000	84,780	162,840	Dec 22 05:42 PM
Linetsky David	President, Network Solutions	Dec 17 '25	Sale	16.49	94	1,550	9,789	Dec 19 05:27 PM
Roberts Evan	President, Provider Solutions	Dec 17 '25	Option Exercise	5.05	50,000	252,316	840,949	Dec 19 05:26 PM
Hui Yvonne	Principal Accounting Officer	Dec 17 '25	Sale	16.25	426	6,922	29,910	Dec 19 05:25 PM
Linetsky David	Member of immediate family of	Dec 17 '25	Proposed Sale	16.49	94	1,550		Dec 17 03:07 PM
Hui Yvonne	Officer	Dec 17 '25	Proposed Sale	16.25	426	6,922		Dec 17 09:45 AM
Gandhi Balaji	Chief Financial Officer	Oct 17 '25	Sale	22.36	885	19,790	98,240	Oct 21 05:02 PM
Hoffman Allison C	General Counsel & Secretary	Oct 17 '25	Sale	22.36	1,241	27,750	135,737	Oct 21 05:00 PM
Indig Chaim	Chief Executive Officer	Oct 17 '25	Sale	22.36	3,163	70,728	1,252,608	Oct 21 04:53 PM
Linetsky David	President, Network Solutions	Oct 17 '25	Sale	22.36	2,059	46,042	171,829	Oct 21 04:50 PM
Roberts Evan	President, Provider Solutions	Oct 17 '25	Sale	22.36	1,888	42,218	724,949	Oct 21 04:48 PM
VanDuyn Amy Beth	SVP, Human Resources	Oct 17 '25	Sale	22.36	639	14,289	111,840	Oct 21 04:46 PM
Gandhi Balaji	Officer	Oct 17 '25	Proposed Sale	22.36	885	19,790		Oct 17 04:31 PM
Indig Chaim	Officer	Oct 17 '25	Proposed Sale	22.36	3,163	70,728		Oct 17 04:26 PM
Hoffman Allison C	Officer	Oct 17 '25	Proposed Sale	22.36	1,241	27,750		Oct 17 04:24 PM
Linetsky David	Officer	Oct 17 '25	Proposed Sale	22.36	2,059	46,042		Oct 17 04:21 PM
Hui Yvonne	Principal Accounting Officer	Oct 15 '25	Sale	23.05	302	6,960	30,336	Oct 17 04:18 PM
VanDuyn Amy Beth	Officer	Oct 17 '25	Proposed Sale	22.36	639	14,289		Oct 17 04:18 PM
Roberts Evan	Officer	Oct 17 '25	Proposed Sale	22.36	1,888	42,218		Oct 17 04:15 PM
Hui Yvonne	Officer	Oct 15 '25	Proposed Sale	23.05	302	6,960		Oct 15 03:17 PM
Linetsky David	President, Network Solutions	Sep 18 '25	Sale	23.94	93	2,226	9,883	Sep 22 04:15 PM
Gandhi Balaji	Chief Financial Officer	Sep 16 '25	Sale	23.28	4,183	97,399	99,125	Sep 18 05:44 PM
Hoffman Allison C	General Counsel & Secretary	Sep 16 '25	Sale	23.28	3,133	72,950	139,037	Sep 18 05:43 PM
Hoffman Allison C	General Counsel & Secretary	Sep 17 '25	Sale	23.50	2,059	48,386	136,978	Sep 18 05:43 PM
Hui Yvonne	Principal Accounting Officer	Sep 16 '25	Sale	23.28	940	21,887	30,638	Sep 18 05:42 PM
Indig Chaim	Chief Executive Officer	Sep 16 '25	Sale	23.28	6,328	147,344	1,255,771	Sep 18 05:40 PM
Linetsky David	President, Network Solutions	Sep 16 '25	Sale	23.28	2,165	50,411	174,952	Sep 18 05:38 PM
Linetsky David	President, Network Solutions	Sep 17 '25	Sale	23.50	1,064	25,004	173,888	Sep 18 05:38 PM
Roberts Evan	President, Provider Solutions	Sep 16 '25	Sale	23.28	3,761	87,573	726,837	Sep 18 05:33 PM
VanDuyn Amy Beth	SVP, Human Resources	Sep 16 '25	Sale	23.28	1,762	41,027	112,479	Sep 18 05:30 PM
Linetsky David	Member of immediate family of	Sep 18 '25	Proposed Sale	23.94	93	2,226		Sep 18 04:12 PM
Linetsky David	Officer	Sep 17 '25	Proposed Sale	23.50	1,064	25,004		Sep 17 10:59 AM
Hoffman Allison C	Officer	Sep 17 '25	Proposed Sale	23.50	2,059	48,386		Sep 17 10:46 AM
Hui Yvonne	Officer	Sep 16 '25	Proposed Sale	23.28	940	21,887		Sep 16 04:21 PM
VanDuyn Amy Beth	Officer	Sep 16 '25	Proposed Sale	23.28	1,762	41,027		Sep 16 04:08 PM
Hoffman Allison C	Officer	Sep 16 '25	Proposed Sale	23.28	3,133	72,950		Sep 16 03:59 PM
Indig Chaim	Officer	Sep 16 '25	Proposed Sale	23.28	6,328	147,344		Sep 16 03:57 PM
Linetsky David	Officer	Sep 16 '25	Proposed Sale	23.28	2,051	47,756		Sep 16 03:56 PM
Linetsky David	Member of immediate family of	Sep 16 '25	Proposed Sale	23.28	114	2,654		Sep 16 03:52 PM
Roberts Evan	Officer	Sep 16 '25	Proposed Sale	23.28	3,761	87,573		Sep 16 03:51 PM
Gandhi Balaji	Officer	Sep 16 '25	Proposed Sale	23.28	4,183	97,399		Sep 16 03:44 PM
Indig Chaim	Chief Executive Officer	Aug 27 '25	Option Exercise	7.24	92,247	668,135	1,343,650	Aug 29 04:12 PM
Indig Chaim	Chief Executive Officer	Aug 28 '25	Option Exercise	7.24	7,746	56,115	1,259,149	Aug 29 04:12 PM
Indig Chaim	Chief Executive Officer	Aug 27 '25	Sale	32.02	92,247	2,953,435	1,251,403	Aug 29 04:12 PM
Indig Chaim	Chief Executive Officer	Aug 28 '25	Sale	32.47	7,746	251,476	1,251,403	Aug 29 04:12 PM
Roberts Evan	President, Provider Solutions	Aug 27 '25	Sale	32.02	45,147	1,445,602	727,768	Aug 29 04:11 PM
Roberts Evan	President, Provider Solutions	Aug 28 '25	Sale	32.46	3,400	110,369	724,368	Aug 29 04:11 PM
Indig Chaim	Officer	Aug 28 '25	Proposed Sale	32.47	7,746	251,476		Aug 28 04:24 PM
Roberts Evan	Officer	Aug 28 '25	Proposed Sale	32.46	3,400	110,369		Aug 28 04:13 PM
Indig Chaim	Officer	Aug 27 '25	Proposed Sale	32.02	92,247	2,953,433		Aug 27 05:12 PM
Roberts Evan	Officer	Aug 27 '25	Proposed Sale	32.02	45,147	1,445,602		Aug 27 04:57 PM
Gandhi Balaji	Chief Financial Officer	Aug 25 '25	Sale	30.01	9,583	287,550	97,078	Aug 27 04:16 PM
VanDuyn Amy Beth	SVP, Human Resources	Aug 25 '25	Sale	30.37	18,573	564,055	110,607	Aug 27 04:14 PM
Weintraub Michael	Director	Aug 25 '25	Option Exercise	5.74	10,000	57,435	165,116	Aug 27 04:12 PM
Weintraub Michael	Director	Aug 25 '25	Sale	30.00	10,000	300,000	158,229	Aug 27 04:12 PM
Linetsky David	President, Network Solutions	Aug 22 '25	Sale	29.73	17,445	518,682	174,002	Aug 26 04:46 PM
VanDuyn Amy Beth	Officer	Aug 25 '25	Proposed Sale	30.37	18,573	564,055		Aug 25 04:21 PM
Gandhi Balaji	Officer	Aug 25 '25	Proposed Sale	30.01	9,583	287,550		Aug 25 04:10 PM

Open in Screener

TDOC

Teladoc Health Inc

Feb 12 • 04:00PM ET

4.47

-0.21 -4.49 %

Healthcare • Health Information Services • USA • NYSE

TDOC Teladoc Health Inc daily Stock Chart

Peers: AMWL DOCS TVRD HIMS GDRX CLOV OSCR ACHC MD RMTI

| Held by: VTI VB IWM VBK VXF AVUV VTWO IWN SCHA DFSV

Index	RUT	P/E	-	EPS (ttm)	-1.28	Insider Own	1.10%	Shs Outstand	177.35M	Perf Week	-5.50%
Market Cap	793.31M	Forward P/E	-	EPS next Y	-0.83	Insider Trans	-4.05%	Shs Float	175.52M	Perf Month	-36.05%
Enterprise Value	1.11B	PEG	-	EPS next Q	-0.18	Inst Own	73.16%	Short Float	15.92%	Perf Quarter	-40.87%
Income	-223.59M	P/S	0.31	EPS this Y	79.92%	Inst Trans	-2.29%	Short Ratio	4.75	Perf Half Y	-39.92%
Sales	2.53B	P/B	0.57	EPS next Y	29.38%	ROA	-6.98%	Short Interest	27.94M	Perf YTD	-36.14%
Book/sh	7.85	P/C	1.09	EPS next 5Y	51.54%	ROE	-15.42%	52W High	15.21 -70.61%	Perf Year	-64.38%
Cash/sh	4.09	P/FCF	2.87	EPS past 3/5Y	-29.04% -33.66%	ROIC	-9.22%	52W Low	4.53 -1.32%	Perf 3Y	-84.74%
Dividend Est.	-	EV/EBITDA	5.83	Sales past 3/5Y	8.13% 35.95%	Gross Margin	55.61%	Volatility	6.37% 5.39%	Perf 5Y	-98.48%
Dividend TTM	-	EV/Sales	0.44	EPS Y/Y TTM	77.85%	Oper. Margin	-7.06%	ATR (14)	0.30	Perf 10Y	-62.50%
Dividend Ex-Date	-	Quick Ratio	2.52	Sales Y/Y TTM	-2.37%	Profit Margin	-8.84%	RSI (14)	21.58	Recom	2.64
Dividend Gr. 3/5Y	- -	Current Ratio	2.61	EPS Q/Q	-44.23%	SMA20	-19.40%	Beta	2.15	Target Price	8.89
Payout	-	Debt/Eq	0.75	Sales Q/Q	-2.20%	SMA50	-32.56%	Rel Volume	1.31	Prev Close	4.68
Employees	5500	LT Debt/Eq	0.74	Earnings	Feb 25 AMC	SMA200	-39.98%	Avg Volume	5.88M	Price	4.47
IPO	Jul 01, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.22% 0.11%	Trades		Volume	7,719,959	Change	-4.49%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Equal Weight	$8.50
Nov-13-25	Initiated	BMO Capital Markets	Market Perform	$8
Jul-25-25	Initiated	Mizuho	Neutral	$10
Nov-15-24	Initiated	Goldman	Buy	$14
Sep-17-24	Reiterated	Jefferies	Hold	$8 → $10
Feb-29-24	Initiated	Cantor Fitzgerald	Overweight	$22
Feb-26-24	Initiated	Leerink Partners	Market Perform	$17
Jan-17-24	Downgrade	DA Davidson	Buy → Neutral	$33 → $22
Jan-03-24	Initiated	Barclays	Overweight	$26
Apr-12-23	Initiated	Stephens	Equal-Weight	$25
Feb-23-23	Upgrade	SVB Securities	Market Perform → Outperform	$34
Oct-24-22	Upgrade	Guggenheim	Sell → Neutral
Sep-16-22	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-07-22	Initiated	Truist	Hold	$35
Aug-17-22	Downgrade	Guggenheim	Neutral → Sell	$25
Aug-12-22	Initiated	DA Davidson	Buy	$45
Aug-02-22	Downgrade	Cowen	Outperform → Market Perform	$58 → $34
Aug-02-22	Downgrade	Berenberg	Buy → Hold	$35
Jul-28-22	Downgrade	Needham	Buy → Hold
Jul-28-22	Downgrade	Goldman	Buy → Neutral	$55 → $36

Show Previous Ratings

Today 09:59AM	Hims & Hers Strengthens Integrated Personalized Digital Care Platform (Zacks)
Feb-11-26 11:56AM	Telehealth stocks pressured as Amazon Pharmacy expands prescription delivery (Investing.com)
11:13AM	HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? (Zacks)
Feb-10-26 06:15PM	Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Feb-05-26 04:30PM	Teladoc Health to Announce Fourth Quarter 2025 Financial Results (GlobeNewswire) +5.92%
02:36PM	Loading…
Feb-04-26 02:36PM	Jim Cramer on Teladoc: "I Don't See Any Reason to Own It" (Insider Monkey)
Feb-02-26 06:15PM	Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-29-26 04:50AM	Chuck Divita on why 2026 is Teladocs execution year (Healthcare Dive)
Jan-28-26 04:30PM	Once Medicare Stops Covering Telehealth Services, Will Teladoc Health Stock be in Trouble? (Motley Fool)
07:10AM	Danaher (DHR) Beats Q4 Earnings and Revenue Estimates (Zacks)
Jan-27-26 06:15PM	Teladoc (TDOC) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks) -6.04%
03:10PM	Why Teladoc (TDOC) Shares Are Plunging Today (StockStory)
10:20AM	Are Telehealth Stocks Set to Tumble in 2026? (Motley Fool)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jan-21-26 10:50PM	2 Beaten-Down Stocks That Could Sink Even More in 2026 (Motley Fool)
08:55AM	Loading…
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jan-20-26 11:04PM	3 Reasons to Avoid TDOC and 1 Stock to Buy Instead (StockStory)
01:00PM	Teladoc and EverQuote Shares Plummet, What You Need To Know (StockStory)
Jan-19-26 12:13PM	Hims & Hers Expands Platform-Led Access to Digital Healthcare (Zacks)
Jan-13-26 06:15PM	Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks) -5.44%
Jan-12-26 06:00AM	Teladoc Health Launches Enhanced 24/7 Care Service (GlobeNewswire)
Jan-08-26 11:34PM	3 Value Stocks with Open Questions (StockStory)
09:54AM	Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell? (Zacks)
Jan-07-26 06:15PM	Why Teladoc (TDOC) Dipped More Than Broader Market Today (Zacks) -5.37%
Jan-05-26 04:30PM	Teladoc Health to Participate in Upcoming Investor Conference (GlobeNewswire) +9.89%
Jan-04-26 11:23AM	3 Reasons to Forget Teladoc Health Stock (Motley Fool)
Dec-30-25 12:41PM	HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand (Zacks)
Dec-29-25 11:35PM	3 Volatile Stocks That Concern Us (StockStory)
Dec-27-25 01:01PM	Down 98% From Its All-Time High? Is It Finally Time to Buy This Former Market Darling? (Motley Fool)
Dec-24-25 12:22PM	HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling? (Zacks)
11:55AM	Loading…
Dec-22-25 11:55AM	Why Teladoc (TDOC) Stock Is Up Today (StockStory)
09:53AM	Barclays Initiates Coverage on Teladoc (TDOC) with Equal Weight at $8.50 (Insider Monkey)
Dec-13-25 11:35AM	Private Markets: Musks SpaceX targets 2026 IPO at valuation of $1.5T (TipRanks)
07:13AM	Forget Teladoc and Buy This Healthcare Stock Instead (Motley Fool)
Dec-11-25 10:32AM	Hims & Hers Expands Its Technology-Driven Personalized Virtual Care (Zacks)
Dec-09-25 11:25AM	Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell? (Zacks)
Dec-01-25 05:57AM	3 Unprofitable Stocks We Approach with Caution (StockStory)
Nov-28-25 11:30AM	Why Is Teladoc (TDOC) Down 14.8% Since Last Earnings Report? (Zacks)
Nov-26-25 04:05PM	Teladoc Health to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-24-25 04:55PM	Teladoc, Angi, Upwork, and ACV Auctions Shares Are Soaring, What You Need To Know (StockStory)
Nov-21-25 11:06AM	Does Teladoc's Acquisition Strategy Boost Growth and Global Footprint? (Zacks)
Nov-20-25 04:55PM	Teladoc and Netflix Shares Are Falling, What You Need To Know (StockStory)
11:42AM	TDOC vs. LFMD: Which Telehealth Stock Is Better for Your Portfolio? (Zacks)
Nov-19-25 10:32PM	Online Marketplace Stocks Q3 Highlights: Teladoc (NYSE:TDOC) (StockStory)
12:24PM	TDOC Partners With TytoCare to Expand At-Home Exam Capabilities (Zacks)
Nov-18-25 11:43AM	Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell? (Zacks)
09:00AM	TytoCare Integrates With Teladoc Health to Augment Virtual Primary and Urgent Care (PR Newswire)
Nov-17-25 11:23AM	Is Teladoc Health Accelerating Growth Through Global Expansion? (Zacks)
Nov-15-25 11:42PM	Teladoc Health Held In-Line Rating in Late Ocotber as Evercore Reversed Price Target Back to $8 (Insider Monkey)
Nov-13-25 03:55PM	Teladoc, MercadoLibre, Reddit, Lyft, and Wayfair Stocks Trade Down, What You Need To Know (StockStory) -5.35%
Nov-11-25 01:26PM	Teladoc Health's Q3 Loss Widens Y/Y on Weak BetterHelp Unit (Zacks)
12:43PM	Hims & Hers Scales Technology-Enabled, Vertically Integrated Care (Zacks)
Nov-10-25 12:47PM	How is Teladoc Health Placed in the Growing Telemedicine Market? (Zacks)
Nov-06-25 04:30PM	Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08 (GlobeNewswire) -5.46%
01:31PM	1 Russell 2000 Stock to Keep an Eye On and 2 Facing Challenges (StockStory)
Nov-05-25 12:23PM	How to Play Teladoc Health Stock Post Q3 Results: Buy, Hold or Sell? (Zacks)
06:45AM	Why Teladoc Stock Zoomed Almost 12% Higher in October (Motley Fool)
12:32AM	The 5 Most Interesting Analyst Questions From Teladoc's Q3 Earnings Call (StockStory)
Nov-04-25 11:42AM	Sovato raises Series B funds to advance remote robotic surgery platform (Medical Device Network)
Nov-03-25 09:24PM	Is This Beaten-Down Stock Finally on the Road to Recovery? (Motley Fool) -5.68%
04:01PM	Why Teladoc (TDOC) Shares Are Getting Obliterated Today (StockStory)
Oct-31-25 07:38AM	Harry Yous Berto Embraces Clinic-in-a-Box with OnMed Event Flash (Exec Edge)
Oct-30-25 06:54PM	Teladoc Finds Its Groove With Strong Q3, AI Push (GuruFocus.com) +6.20%
04:11PM	Teladoc Health Inc (TDOC) Q3 2025 Earnings Call Highlights: Navigating Challenges and Seizing ... (GuruFocus.com)
02:35PM	Why Teladoc (TDOC) Stock Is Trading Up Today (StockStory)
09:16AM	TDOC Q3 CY2025 Deep Dive: Insurance Pivot, International Growth, and Margin Pressures (StockStory)
09:00AM	Teladoc expands insurance coverage at mental health unit BetterHelp (Healthcare Dive)
Oct-29-25 07:00PM	Teladoc (TDOC) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:45PM	Teladoc (TDOC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:45PM	Teladoc: Q3 Earnings Snapshot (Associated Press Finance)
04:27PM	Teladoc's (NYSE:TDOC) Q3 Earnings Results: Revenue In Line With Expectations (StockStory)
04:05PM	Teladoc Health Reports Third Quarter 2025 Results (GlobeNewswire)
Oct-28-25 09:15AM	Wall Street's Insights Into Key Metrics Ahead of Teladoc (TDOC) Q3 Earnings (Zacks) -7.21%
07:45AM	GeneDx Holdings Corp. (WGS) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 11:04PM	Teladoc (TDOC) Q3 Earnings Report Preview: What To Look For (StockStory)
11:44AM	Teladoc (TDOC) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Oct-24-25 04:25PM	Teladoc, Robinhood, and Reddit Shares Skyrocket, What You Need To Know (StockStory) +10.00%
05:58AM	Teladoc finance chief to step down (Healthcare Dive)
Oct-23-25 04:05PM	Teladoc Health Announces Chief Financial Officer Transition (GlobeNewswire)
11:29AM	Stock Market Today: Quantum Computing Stocks Take Center Stage After Trump Bombshell (TheStreet)
10:00AM	Organon (OGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-25 10:00AM	Teladoc (TDOC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-17-25 06:15PM	Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know (Zacks) -5.43% +5.28%
10:18AM	Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? (Zacks)
06:17AM	Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health (Motley Fool)
Oct-16-25 12:36PM	Hims & Hers Elevates Technology-Driven Healthcare Accessibility (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
03:23AM	Zacks.com featured highlights include United Natural Foods, Teladoc Health, Supernus and BRP (Zacks)
12:01AM	3 Reasons TDOC is Risky and 1 Stock to Buy Instead (StockStory)
Oct-15-25 04:30PM	Teladoc Health to Announce Third Quarter 2025 Financial Results (GlobeNewswire)
03:08PM	Can 4 Relative Price Strength Stocks Defy Market Swings? (Zacks)
09:35AM	Teladoc (TDOC) Recently Broke Out Above the 20-Day Moving Average (Zacks)
09:30AM	Teladoc (TDOC) Just Reclaimed the 200-Day Moving Average (Zacks)
09:17AM	Teladoc Health Expands Clarity Platform With Workplace Safety Tool (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:50AM	Looking for a Fast-paced Momentum Stock at a Bargain? Consider Teladoc (TDOC) (Zacks)
Oct-14-25 01:13PM	Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell? (Zacks) +8.24%
01:06PM	Why Teladoc (TDOC) Stock Is Trading Up Today (StockStory)
06:00AM	Teladoc Health Adds Workplace Safety Capability to its AI-Enabled Clarity Monitoring Solution for Hospitals and Health Systems (GlobeNewswire)
Oct-10-25 11:50AM	3 Medical Service Industry Stocks Poised to Counter Workforce Issues (Zacks) -9.60%

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Catapano Joseph Ronald	Chief Accounting Officer	Jan 05 '26	Sale	7.14	758	5,416	6,686	Jan 06 04:05 PM
DIVITA CHARLES III	CHIEF EXECUTIVE OFFICER	Dec 11 '25	Sale	7.63	17,138	130,837	201,036	Dec 11 04:23 PM
DIVITA CHARLES III	Officer	Dec 11 '25	Proposed Sale	7.63	17,138	130,837		Dec 11 03:46 PM
Rodrigues Fernando M.	President of BetterHelp	Dec 03 '25	Sale	7.48	4,209	31,483	0	Dec 03 09:04 PM
Rodrigues Fernando M.	President of BetterHelp	Dec 02 '25	Sale	7.49	2,324	17,402	4,209	Dec 03 09:04 PM
Vandervoort Adam C	CHIEF LEGAL OFFICER, SECRETARY	Dec 02 '25	Sale	7.49	5,720	42,831	80,732	Dec 03 09:04 PM
Nueno Carlos	President, International	Dec 02 '25	Sale	7.49	3,897	29,181	27,175	Dec 03 09:03 PM
Bliss Kelly	President, U.S. Group Health	Dec 02 '25	Sale	7.49	4,582	34,310	60,054	Dec 03 09:03 PM
Rodrigues Fernando M.	Officer	Dec 03 '25	Proposed Sale	7.48	4,209	31,483		Dec 03 09:46 AM
Vandervoort Adam C	Officer	Dec 02 '25	Proposed Sale	7.49	5,720	42,833		Dec 02 04:25 PM
Nueno Carlos	Officer	Dec 02 '25	Proposed Sale	7.49	3,897	29,182		Dec 02 04:22 PM
Bliss Kelly	Officer	Dec 02 '25	Proposed Sale	7.49	4,582	34,311		Dec 02 04:15 PM
Rodrigues Fernando M.	Officer	Dec 02 '25	Proposed Sale	7.49	2,324	17,403		Dec 02 04:14 PM
Paulus Kenneth H	Director	Nov 14 '25	Buy	6.94	10,000	69,400	10,000	Nov 17 04:05 PM
Catapano Joseph Ronald	Chief Accounting Officer	Oct 02 '25	Sale	7.88	2,972	23,434	5,361	Oct 03 04:05 PM
DIVITA CHARLES III	CHIEF EXECUTIVE OFFICER	Sep 11 '25	Sale	7.59	16,787	127,435	179,014	Sep 11 04:04 PM
DIVITA CHARLES III	Officer	Sep 11 '25	Proposed Sale	7.59	16,787	127,435		Sep 11 03:28 PM
Rodrigues Fernando M.	President of BetterHelp	Sep 03 '25	Sale	7.59	4,149	31,491	0	Sep 03 04:05 PM
Rodrigues Fernando M.	President of BetterHelp	Sep 02 '25	Sale	7.58	2,383	18,075	4,149	Sep 03 04:05 PM
Nueno Carlos	President, International	Sep 02 '25	Sale	7.58	3,998	30,325	22,359	Sep 03 04:05 PM
Vandervoort Adam C	CHIEF LEGAL OFFICER, SECRETARY	Sep 02 '25	Sale	7.58	5,867	44,501	75,179	Sep 03 04:05 PM
Bliss Kelly	President, U.S. Group Health	Sep 02 '25	Sale	7.58	4,700	35,650	55,101	Sep 03 04:05 PM
Murthy Mala	CHIEF FINANCIAL OFFICER	Sep 02 '25	Sale	7.58	12,846	97,437	142,385	Sep 03 04:05 PM
Rodrigues Fernando M.	Officer	Sep 03 '25	Proposed Sale	7.59	4,149	31,491		Sep 03 11:45 AM
Rodrigues Fernando M.	Officer	Sep 02 '25	Proposed Sale	7.59	2,383	18,076		Sep 02 04:33 PM
Bliss Kelly	Officer	Sep 02 '25	Proposed Sale	7.59	4,700	35,651		Sep 02 04:15 PM
Nueno Carlos	Officer	Sep 02 '25	Proposed Sale	7.59	3,998	30,326		Sep 02 04:09 PM
Vandervoort Adam C	Officer	Sep 02 '25	Proposed Sale	7.59	5,867	44,503		Sep 02 04:05 PM
Murthy Mala	Officer	Sep 02 '25	Proposed Sale	7.59	12,846	97,441		Sep 02 03:59 PM
Rodrigues Fernando M.	President of BetterHelp	Jun 03 '25	Sale	6.91	4,174	28,842	0	Jun 03 05:37 PM
Rodrigues Fernando M.	President of BetterHelp	Jun 02 '25	Sale	6.86	2,358	16,176	4,174	Jun 03 05:37 PM
Vandervoort Adam C	CHIEF LEGAL OFFICER, SECRETARY	Jun 02 '25	Sale	6.86	5,808	39,843	69,773	Jun 03 05:37 PM
Bliss Kelly	President, U.S. Group Health	Jun 02 '25	Sale	6.86	4,653	31,920	50,266	Jun 03 05:36 PM
Murthy Mala	CHIEF FINANCIAL OFFICER	Jun 02 '25	Sale	6.86	13,856	95,052	132,443	Jun 03 05:36 PM
Nueno Carlos	President, International	Jun 02 '25	Sale	6.86	3,958	27,152	17,645	Jun 03 05:36 PM
Rodrigues Fernando M.	Officer	Jun 03 '25	Proposed Sale	6.91	4,174	28,842		Jun 03 10:53 AM
Murthy Mala	Officer	Jun 02 '25	Proposed Sale	6.86	13,856	95,052		Jun 02 03:46 PM
Rodrigues Fernando M.	Officer	Jun 02 '25	Proposed Sale	6.86	2,358	16,176		Jun 02 03:45 PM
Vandervoort Adam C	Officer	Jun 02 '25	Proposed Sale	6.86	5,808	39,843		Jun 02 03:44 PM
Bliss Kelly	Officer	Jun 02 '25	Proposed Sale	6.86	4,653	31,920		Jun 02 03:43 PM
Nueno Carlos	Officer	Jun 02 '25	Proposed Sale	6.86	3,958	27,152		Jun 02 03:38 PM
Murthy Mala	CHIEF FINANCIAL OFFICER	Apr 07 '25	Sale	6.81	7,494	51,012	121,467	Apr 08 04:23 PM
Murthy Mala	Officer	Apr 07 '25	Proposed Sale	6.81	7,494	51,012		Apr 07 05:15 PM
Murthy Mala	CHIEF FINANCIAL OFFICER	Mar 20 '25	Sale	8.42	20,586	173,416	116,309	Mar 21 04:20 PM
Vandervoort Adam C	CHIEF LEGAL OFFICER, SECRETARY	Mar 20 '25	Sale	8.42	11,011	92,757	64,308	Mar 21 04:20 PM
Rodrigues Fernando M.	President of BetterHelp	Mar 21 '25	Sale	8.00	2,663	21,304	0	Mar 21 04:19 PM
Rodrigues Fernando M.	President of BetterHelp	Mar 20 '25	Sale	8.42	1,503	12,661	2,663	Mar 21 04:19 PM
Bliss Kelly	President, U.S. Group Health	Mar 20 '25	Sale	8.42	9,470	79,775	45,384	Mar 21 04:19 PM
Nueno Carlos	President, International	Mar 20 '25	Sale	8.42	8,266	69,633	12,891	Mar 21 04:19 PM
Rodrigues Fernando M.	Officer	Mar 21 '25	Proposed Sale	8.00	2,663	21,304		Mar 21 10:16 AM
Rodrigues Fernando M.	Officer	Mar 20 '25	Proposed Sale	8.42	1,503	12,661		Mar 20 03:25 PM
Bliss Kelly	Officer	Mar 20 '25	Proposed Sale	8.42	9,470	79,773		Mar 20 03:13 PM
Murthy Mala	Officer	Mar 20 '25	Proposed Sale	8.42	20,586	173,412		Mar 20 03:12 PM
Vandervoort Adam C	Officer	Mar 20 '25	Proposed Sale	8.42	11,011	92,754		Mar 20 03:10 PM
Nueno Carlos	Officer	Mar 20 '25	Proposed Sale	8.42	8,266	69,631		Mar 20 03:09 PM
Rodrigues Fernando M.	President of BetterHelp	Mar 05 '25	Sale	9.20	3,558	32,734	0	Mar 06 04:04 PM
Rodrigues Fernando M.	Officer	Mar 05 '25	Proposed Sale	9.20	3,558	32,734		Mar 05 09:44 AM
Rodrigues Fernando M.	President of BetterHelp	Mar 03 '25	Sale	9.68	1,933	18,719	3,558	Mar 04 04:07 PM
Murthy Mala	CHIEF FINANCIAL OFFICER	Mar 03 '25	Sale	9.68	8,630	83,573	99,962	Mar 04 04:07 PM
Nueno Carlos	President, International	Mar 03 '25	Sale	9.68	2,347	22,728	2,932	Mar 04 04:06 PM
Bliss Kelly	President, U.S. Group Health	Mar 03 '25	Sale	9.68	2,904	28,122	35,421	Mar 04 04:06 PM
Vandervoort Adam C	CHIEF LEGAL OFFICER, SECRETARY	Mar 03 '25	Sale	9.68	3,935	38,107	53,919	Mar 04 04:06 PM
Bliss Kelly	Officer	Mar 03 '25	Proposed Sale	9.68	2,904	28,124		Mar 03 04:29 PM
Murthy Mala	Officer	Mar 03 '25	Proposed Sale	9.68	8,630	83,576		Mar 03 04:22 PM
Nueno Carlos	Officer	Mar 03 '25	Proposed Sale	9.68	2,347	22,729		Mar 03 04:21 PM
Rodrigues Fernando M.	Officer	Mar 03 '25	Proposed Sale	9.68	1,933	18,720		Mar 03 04:20 PM
Vandervoort Adam C	Officer	Mar 03 '25	Proposed Sale	9.68	3,935	38,108		Mar 03 04:17 PM

Open in Screener

JAZZ

Jazz Pharmaceuticals plc

Feb 12 • 04:00PM ET

166.29

+0.05 0.03 %

Healthcare • Biotechnology • Ireland • NASD

JAZZ Jazz Pharmaceuticals plc daily Stock Chart

Peers: VRTX REGN BIIB INCY GILD BMRN NBIX EXEL UTHR SAGE

| Held by: IJH VTI VB VBR VXF MDY IJK COWG SPMD CALF

Index	-	P/E	-	EPS (ttm)	-6.07	Insider Own	4.67%	Shs Outstand	60.74M	Perf Week	1.92%
Market Cap	10.10B	Forward P/E	7.44	EPS next Y	22.35	Insider Trans	-4.55%	Shs Float	57.93M	Perf Month	2.38%
Enterprise Value	13.49B	PEG	1.13	EPS next Q	6.53	Inst Own	100.32%	Short Float	9.78%	Perf Quarter	21.28%
Income	-368.48M	P/S	2.43	EPS this Y	-60.75%	Inst Trans	-1.43%	Short Ratio	4.79	Perf Half Y	41.98%
Sales	4.16B	P/B	2.55	EPS next Y	172.39%	ROA	-3.12%	Short Interest	5.66M	Perf YTD	-2.18%
Book/sh	65.18	P/C	4.94	EPS next 5Y	6.59%	ROE	-9.06%	52W High	182.99 -9.13%	Perf Year	22.78%
Cash/sh	33.67	P/FCF	7.56	EPS past 3/5Y	- -1.00%	ROIC	-4.42%	52W Low	95.49 74.14%	Perf 3Y	10.85%
Dividend Est.	-	EV/EBITDA	11.23	Sales past 3/5Y	9.56% 13.48%	Gross Margin	73.01%	Volatility	2.26% 2.72%	Perf 5Y	-0.73%
Dividend TTM	-	EV/Sales	3.24	EPS Y/Y TTM	-179.96%	Oper. Margin	12.39%	ATR (14)	4.53	Perf 10Y	46.15%
Dividend Ex-Date	-	Quick Ratio	1.44	Sales Y/Y TTM	4.14%	Profit Margin	-8.86%	RSI (14)	49.95	Recom	1.28
Dividend Gr. 3/5Y	- -	Current Ratio	1.65	EPS Q/Q	19.88%	SMA20	-0.34%	Beta	0.25	Target Price	218.20
Payout	0.00%	Debt/Eq	1.37	Sales Q/Q	6.74%	SMA50	-0.63%	Rel Volume	0.73	Prev Close	166.24
Employees	2800	LT Debt/Eq	1.11	Earnings	Feb 24 AMC	SMA200	23.14%	Avg Volume	1.18M	Price	166.29
IPO	Jun 01, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.72% 1.35%	Trades		Volume	859,094	Change	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Downgrade	UBS	Buy → Neutral	$188
Jul-15-25	Initiated	Deutsche Bank	Buy	$152
Mar-07-25	Upgrade	UBS	Neutral → Buy	$145 → $179
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$130 → $170
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$140 → $175
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186

Show Previous Ratings

Feb-11-26 08:36AM	Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? (Zacks)
Feb-10-26 04:15PM	Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 (PR Newswire)
Feb-09-26 07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-03-26 07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
06:55AM	Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial (Insider Monkey)
12:39PM	Loading…
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-16-26 06:24AM	Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading (BioPharma Dive)
Jan-15-26 12:41PM	JPM26: Jazz sells PRV for $200m, targets deals in 2026 (Pharmaceutical Technology)
Jan-13-26 07:43AM	Jazz Pharmaceuticals price target raised to $235 from $210 at Needham (TipRanks)
Jan-09-26 12:19PM	Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 (MarketBeat)
Jan-08-26 07:50PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -5.38%
04:05PM	Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer (PR Newswire)
Jan-06-26 01:32PM	Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit (PR Newswire)
10:37PM	Loading…
Dec-28-25 10:37PM	Reflecting On Pharmaceuticals Stocks' Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) (StockStory)
Dec-17-25 11:03PM	3 Reasons JAZZ is Risky and 1 Stock to Buy Instead (StockStory)
04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Events (PR Newswire)
Dec-05-25 11:30AM	Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue? (Zacks)
09:00AM	Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting (PR Newswire)
07:12AM	Trials, Sales Wins Sends Jazz Pharmaceuticals Higher (FX Empire)
Dec-02-25 04:05PM	Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Nov-26-25 09:13AM	Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner (Zacks)
Nov-24-25 09:41AM	Booking, Carvana upgraded: Wall Street's top analyst calls (The Fly)
09:20AM	Here are Mondays Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More (24/7 Wall St.)
Nov-20-25 01:37AM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Nov-18-25 04:15PM	Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (PR Newswire) +6.13%
12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
03:38AM	Zymeworks to change course, pursue royalty-driven biotech model (BioPharma Dive)
12:43AM	Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial (Insider Monkey)
07:29PM	Loading…
Nov-17-25 07:29PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) +20.57%
04:44PM	Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer (Investor's Business Daily)
04:13PM	Stocks to Watch Recap: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
11:41AM	Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today (StockStory)
09:35AM	Stocks to Watch Monday: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
09:15AM	Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention (Zacks)
08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (PR Newswire)
Nov-12-25 12:36AM	The Top 5 Analyst Questions From Jazz Pharmaceuticals's Q3 Earnings Call (StockStory)
Nov-11-25 07:45AM	Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 (PR Newswire)
Nov-06-25 10:50AM	JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View (Zacks)
12:33AM	JAZZ Q3 Deep Dive: New Drug Launches and Portfolio Expansion Drive Strong Results (StockStory)
12:01AM	Jazz Pharmaceuticals PLC (JAZZ) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Nov-05-25 07:00PM	Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:32PM	Jazz: Q3 Earnings Snapshot (Associated Press Finance)
04:25PM	Jazz Pharmaceuticals's (NASDAQ:JAZZ) Q3: Beats On Revenue (StockStory)
04:05PM	Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
Nov-04-25 10:28AM	AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Nov-03-25 10:17PM	Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q3 Results Tomorrow (StockStory)
Oct-29-25 10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 04:05PM	Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors (PR Newswire)
Oct-24-25 12:02AM	3 Reasons to Sell JAZZ and 1 Stock to Buy Instead (StockStory)
Oct-22-25 04:15PM	Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 (PR Newswire)
Oct-21-25 06:55AM	Iambic partners with Jazz; Merck breaks ground on $3B plant (BioPharma Dive)
Oct-16-25 02:14PM	Praxis Precision's tremor-drug trial has succeeded where others have failed. The stock is skyrocketing. (MarketWatch)
Oct-06-25 01:13PM	Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer (Zacks)
Oct-02-25 06:37PM	FDA Approves Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (PR Newswire)
01:53AM	Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data (Insider Monkey)
Oct-01-25 11:10AM	Headlines Boost Pharma Stocks. Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Speak to Rally Into Year End (Barrons.com)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
Sep-27-25 12:59AM	Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data (Insider Monkey)
Sep-24-25 08:45AM	Here's Why JAZZ Stock Is an Unconventional Cannabis Investment (Zacks)
Sep-23-25 07:11PM	Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval (Insider Monkey)
Sep-22-25 07:45AM	Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses (PR Newswire)
Sep-16-25 09:30AM	Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors (Insider Monkey)
Sep-09-25 07:45AM	Modeyso (dordaviprone) Included in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma (PR Newswire)
Sep-02-25 01:34AM	Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update (Insider Monkey)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
05:04AM	Jazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso Brain Cancer Therapy (Insider Monkey)
Aug-28-25 11:49PM	Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355 (Insider Monkey)
Aug-22-25 11:57PM	BofA Raises PT on Jazz Pharmaceuticals (JAZZ) to $225 From $217 (Insider Monkey)
06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-21-25 04:15PM	Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
09:49AM	JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug (Zacks)
Aug-20-25 04:15PM	Jazz Pharmaceuticals to Host Modeyso (dordaviprone) Investor Webcast on August 27, 2025 (PR Newswire)
07:30AM	Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 (PR Newswire)
Aug-19-25 07:17PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Aug-17-25 11:35PM	Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks (StockStory)
Aug-14-25 04:03AM	United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis (GlobeNewswire)
Aug-13-25 04:30PM	Onco360 adds Modeyso (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider (GlobeNewswire)
12:16AM	The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-12-25 11:48PM	JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook (StockStory)
Aug-08-25 09:15AM	Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock (Zacks)
05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
Aug-07-25 03:35PM	Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today (StockStory) +5.81%
05:00AM	FDA gives accelerated approval to Jazz Pharmas diffuse midline glioma therapy (Pharmaceutical Technology)
Aug-06-25 07:08PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -6.42%
03:07PM	Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma (PR Newswire)
09:22AM	JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut (Zacks)
03:29AM	Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... (GuruFocus.com)
Aug-05-25 06:30PM	Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
06:13PM	Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Q2 In Line With Expectations But Stock Drops (StockStory)
05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Jazz: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
Aug-03-25 11:01PM	Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-30-25 11:44AM	Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains 'Buy' Rating (Insider Monkey)
10:00AM	Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth (Zacks)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henderson Mary Elizabeth	SVP, Technical Operations	Dec 09 '25	Sale	169.51	2,238	379,366	19,508	Dec 11 05:19 PM
MARY ELIZABETH HENDERSON	Officer	Dec 09 '25	Proposed Sale	169.51	2,238	379,365		Dec 09 06:52 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Option Exercise	140.67	4,500	633,015	11,512	Dec 09 05:25 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Sale	171.20	4,660	797,783	7,012	Dec 09 05:25 PM
PATRICIA CARR	Officer	Dec 05 '25	Proposed Sale	171.20	4,660	797,783		Dec 05 04:03 PM
O'Keefe Kenneth W	Director	Dec 02 '25	Proposed Sale	176.59	1,249	220,561		Dec 01 08:55 PM
COZADD BRUCE C	Director	Nov 26 '25	Option Exercise	123.36	77,500	9,560,400	470,832	Dec 01 06:14 PM
COZADD BRUCE C	Director	Nov 26 '25	Sale	177.81	77,500	13,780,337	393,332	Dec 01 06:14 PM
BRUCE COZADD	Director	Nov 26 '25	Proposed Sale	177.81	77,500	13,780,337		Nov 26 05:37 PM
McSharry Heather Ann	Director	Nov 20 '25	Option Exercise	138.08	3,415	471,543	23,864	Nov 24 05:47 PM
McSharry Heather Ann	Director	Nov 20 '25	Sale	177.78	3,415	607,127	20,449	Nov 24 05:47 PM
COZADD BRUCE C	Director	Nov 18 '25	Sale	181.09	18,000	3,259,538	390,826	Nov 20 08:03 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Option Exercise	136.18	5,250	714,945	12,262	Nov 20 06:13 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Sale	182.06	5,319	968,402	7,012	Nov 20 06:13 PM
Winningham Rick E	Director	Nov 18 '25	Sale	180.86	5,500	994,728	8,893	Nov 20 05:54 PM
HEATHER MCSHARRY	Director	Nov 20 '25	Proposed Sale	177.78	3,415	607,127		Nov 20 04:05 PM
Henderson Mary Elizabeth	Officer	Nov 19 '25	Proposed Sale	127.23	2,961	376,740		Nov 19 08:59 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Nov 17 '25	Sale	168.26	7,159	1,204,573	72,628	Nov 19 08:31 PM
Bruce C Cozadd	Officer	Nov 18 '25	Proposed Sale	181.09	18,000	3,259,537		Nov 18 07:08 PM
RICK WINNINGHAM	Director	Nov 18 '25	Proposed Sale	180.86	5,500	994,728		Nov 18 05:20 PM
PATRICIA CARR	Officer	Nov 18 '25	Proposed Sale	182.06	5,319	968,402		Nov 18 04:59 PM
ROBERT IANNONE	Officer	Nov 17 '25	Proposed Sale	168.26	7,159	1,204,573		Nov 17 04:06 PM
COZADD BRUCE C	Director	Oct 03 '25	Sale	140.00	3,500	490,000	408,826	Oct 03 09:27 PM
COZADD BRUCE C	Director	Oct 01 '25	Sale	131.78	2,000	263,560	412,326	Oct 03 09:27 PM
Bruce C Cozadd	Officer	Oct 03 '25	Proposed Sale	140.00	3,500	490,000		Oct 03 04:10 PM
COZADD BRUCE C	Director	Sep 02 '25	Sale	128.62	6,000	771,690	429,973	Sep 04 05:48 PM
Winningham Rick E	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 03:02 PM
Kennedy Patrick	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:56 PM
ENRIGHT PATRICK G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:46 PM
RIEDEL NORBERT G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:40 PM
Smith Mark Douglas	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:33 PM
Hamill Laura	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:26 PM
O'Keefe Kenneth W	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:20 PM
Cook Jennifer E.	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:13 PM
McSharry Heather Ann	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:06 PM
ORiordan Anne	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:00 PM
COZADD BRUCE C	Chairman & CEO	Aug 01 '25	Sale	113.21	1,000	113,210	435,973	Aug 05 04:54 PM
COZADD BRUCE C	Officer	Aug 01 '25	Proposed Sale	121.80	9,000	1,096,210		Aug 01 03:28 PM
COZADD BRUCE C	Chairman & CEO	Jul 01 '25	Sale	107.63	1,000	107,630	436,973	Jul 03 02:56 PM
COZADD BRUCE C	Officer	Jul 01 '25	Proposed Sale	107.63	1,000	107,630		Jul 01 04:15 PM
COZADD BRUCE C	Chairman & CEO	Jun 03 '25	Sale	110.00	500	55,000	437,973	Jun 04 04:50 PM
COZADD BRUCE C	Chairman & CEO	Jun 02 '25	Sale	107.90	500	53,950	438,473	Jun 04 04:50 PM
COZADD BRUCE C	Officer	Jun 02 '25	Proposed Sale	108.95	1,000	108,950		Jun 02 05:03 PM
Mulligan Seamus	Director	May 09 '25	Buy	98.26	100,000	9,826,120	100,000	May 13 06:51 PM
Mulligan Seamus	Director	May 12 '25	Buy	103.00	1,621	166,962	101,621	May 13 06:51 PM
COZADD BRUCE C	Chairman & CEO	May 01 '25	Sale	116.35	1,000	116,350	439,307	May 05 07:00 PM
COZADD BRUCE C	Chairman & CEO	May 02 '25	Sale	120.00	500	60,000	438,807	May 05 07:00 PM
COZADD BRUCE C	Officer	May 01 '25	Proposed Sale	117.57	1,500	176,350		May 01 04:09 PM
COZADD BRUCE C	Chairman & CEO	Apr 01 '25	Sale	123.75	1,500	185,625	440,307	Apr 03 05:32 PM
COZADD BRUCE C	Officer	Apr 01 '25	Proposed Sale	125.31	2,000	250,625		Apr 01 04:32 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 10 '25	Sale	138.41	2,403	332,605	79,621	Mar 12 02:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 10 '25	Sale	137.81	1,140	157,103	7,012	Mar 11 06:17 PM
Iannone Robert	Officer	Mar 10 '25	Proposed Sale	145.00	1,767	256,215		Mar 10 06:01 PM
Carr Patricia	Officer	Mar 10 '25	Proposed Sale	137.81	1,140	157,103		Mar 10 05:36 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 07 '25	Sale	138.60	7,080	981,298	82,024	Mar 07 06:49 PM
ROBERT IANNONE	Officer	Mar 07 '25	Proposed Sale	138.73	5,466	758,305		Mar 07 05:14 PM
Iannone Robert	Officer	Mar 07 '25	Proposed Sale	142.26	4,017	571,476		Mar 07 05:04 PM
Henderson Mary Elizabeth	Officer	Mar 07 '25	Proposed Sale	139.00	1,295	180,005		Mar 07 03:15 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Option Exercise	113.77	4,813	547,562	12,737	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Sale	144.42	4,813	695,075	8,237	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 28 '25	Sale	143.29	773	110,767	9,485	Mar 03 07:21 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 27 '25	Sale	144.87	3,800	550,506	33,318	Mar 03 07:18 PM
COZADD BRUCE C	Chairman & CEO	Mar 03 '25	Sale	144.25	6,500	937,625	464,058	Mar 03 07:13 PM
COZADD BRUCE C	Officer	Mar 03 '25	Proposed Sale	144.25	6,500	937,625		Mar 03 04:44 PM
Carr Patricia	Officer	Feb 28 '25	Proposed Sale	143.30	773	110,767		Feb 28 05:43 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	139.00	1,641	228,099		Feb 27 08:05 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	144.42	4,813	695,075		Feb 27 05:04 PM
Patil Neena M	Officer	Feb 27 '25	Proposed Sale	144.87	3,800	550,518		Feb 27 04:56 PM

PHR

Phreesia Inc

TDOC

Teladoc Health Inc

JAZZ

Jazz Pharmaceuticals plc

Upgrade your FINVIZ experience